Sophiris Bio Inc (NASDAQ:SPHS) Short Interest Up 5.2% in May

Sophiris Bio Inc (NASDAQ:SPHS) saw a significant increase in short interest in the month of May. As of May 31st, there was short interest totalling 1,878,200 shares, an increase of 5.2% from the April 30th total of 1,786,100 shares. Based on an average daily volume of 127,800 shares, the short-interest ratio is currently 14.7 days. Approximately 6.3% of the company’s stock are sold short.

Shares of NASDAQ:SPHS traded up $0.10 during midday trading on Friday, reaching $1.05. 141,475 shares of the company’s stock traded hands, compared to its average volume of 298,824. The company has a debt-to-equity ratio of 2.93, a current ratio of 2.00 and a quick ratio of 2.00. Sophiris Bio has a one year low of $0.71 and a one year high of $3.49. The stock’s 50 day moving average price is $0.83.

Sophiris Bio (NASDAQ:SPHS) last announced its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.02. On average, sell-side analysts anticipate that Sophiris Bio will post -0.36 earnings per share for the current year.

SPHS has been the topic of a number of recent research reports. Maxim Group reissued a “hold” rating on shares of Castle Brands in a research note on Wednesday, June 19th. ValuEngine raised XCel Brands from a “sell” rating to a “hold” rating in a research note on Tuesday, July 9th.

A hedge fund recently raised its stake in Sophiris Bio stock. Geode Capital Management LLC increased its holdings in shares of Sophiris Bio Inc (NASDAQ:SPHS) by 14.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 243,523 shares of the biopharmaceutical company’s stock after purchasing an additional 31,579 shares during the quarter. Geode Capital Management LLC owned approximately 0.81% of Sophiris Bio worth $202,000 at the end of the most recent reporting period. 8.27% of the stock is owned by institutional investors.

About Sophiris Bio

Sophiris Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer.

Further Reading: Can individual investors take part in an IPO?

Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with's FREE daily email newsletter.